<DOC>
	<DOCNO>NCT00444951</DOCNO>
	<brief_summary>This study conduct among adolescent Saudi Arabia previously receive one dose A , C , Y , W 135 least one dose A , C meningococcal polysaccharide vaccine . This study evaluate booster administration Menactra® ( Meningococcal A , C , Y , W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine ) compare Mencevax® ( Meningococcal A , C , Y , W 135 Polysaccharide vaccine ) term serum bactericidal antibody response .</brief_summary>
	<brief_title>Immunogenicity Safety Menactra® Vaccine Adolescents Saudi Arabia</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy , determine medical history physical examination . Aged 16 19 year day inclusion ( 16th birthday 1 day 20th birthday inclusive ) . For Menactra® Mencevax® group , one dose quadrivalent ( A , C , Y , W 135 ) least one dose bivalent ( A , C ) meningococcal polysaccharide vaccine meningococcal vaccine receive less 2 year prior enrollment . For Control group , previous history meningococcal vaccination . Informed consent form sign parent ( ) legal representative subject 18 year sign subject him/herself subject 18 year old Able provide vaccination log available vaccination record Health Center Able attend schedule visit comply trial procedure Serious chronic disease ( i.e. , cardiac , renal , neurologic , metabolic , rheumatologic , psychiatric , etc . ) Known suspect impairment immunologic function . Acute medical illness without fever within last 72 hour oral temperature ≥ 37.5°C time inclusion . Administration immune globulin blood product within last three month , injected oral corticosteroid immunomodulatory therapy within six week study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day may include trial provide received one course within last two week prior enrollment . Oral inject antibiotic therapy within 72 hour prior vaccination Received vaccine 14day period prior study vaccination , schedule receive vaccination 14day period study vaccination . Previous history document invasive meningococcal disease . Systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance Participation another clinical trial 4 week precede trial vaccination Planned participation another clinical trial present trial period Any condition , , opinion investigator , would pose health risk subject , interfere evaluation vaccine . Personal family history Guillain Barré syndrome . For female , know suspect pregnant time inclusion</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>N meningitidis</keyword>
</DOC>